Recro Signs Development and Manufacturing Deal with U.S. Government

Recro Pharma, a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, has been awarded a new formulation development and cGMP manufacturing contract from a key department of the U.S. government. The contract focuses on supporting clinical development of a topical dermal treatment for the prevention of skin cancer.

Under terms of the new, multi-year, $1.5 million contract, the company will formulate, manufacture and supply a topical dermal drug product containing a prespecified active pharmaceutical ingredient (API), as well as a matching placebo, for a planned cancer prevention clinical study. These activities will include analytical method development, formulation, cGMP clinical trial material manufacturing, packaging and labeling services to support the planned clinical trial, which is designed to evaluate the effects of chemoprevention with the investigational compound on the recurrence of basal cell carcinoma.

“We are pleased to have been selected to support this important clinical research program focused on a preventative skin cancer therapy,” said David Enloe, CEO, Recro. “The scope of work associated with this new contract will allow Recro to call upon a broad range of our capabilities from analytical development and formulation through to key clinical trial material manufacturing and packaging. This agreement is the latest evidence of the traction our sales team is generating in growing our base of business, which includes key relationships with not only pharmaceutical and biotech companies but also important federal government agencies.”